be visible on the BioBusiness market ISSN 2300-0228

Log in | Register

Pivotal announces participation in two clinical trials with a novel investigational immunotherapy drug to treat melanoma and lung cancer
Impressions from the visit to Wageningen, the specter of famine, CRISPR Cas9 to the rescue!
Reach out to potential partners and customers in the Danish-Swedish life science cluster, Medicon Valley
Central European Healthcare Expo (20-21.05.2020 Global Expo Warsaw)
The world of healthcare ...

All articles

Filters:

Show search box

2015-11-23

A TALEN(T) for treating leukaemia

A TALEN(T) for treating leukaemia

Genome editing with the use of TALENs – the artificial restriction enzymes – was employed for the world first time to cure acute lymphoblastic leukaemia. TALENs helped to modify T cells obtained from a healthy donor in order to beat cancer cells, remaining invisible to immune system and immunosuppres... Read more

Tags genetic engineering , gene therapy , T cells , UCART19 , acute lymphoblastic leukaemia , TALEN , genome editing